XML 20 R50.htm IDEA: XBRL DOCUMENT v3.2.0.727
Business Segment Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Apr. 30, 2015
Apr. 30, 2014
Net revenue $ 8,863 $ 11,550
Sales and marketing costs (4,283) (3,155)
Stock compensation expense (3,162) (2,807)
Personalized Oncology Solutions [Member]    
Net revenue 1,663 2,264
Direct cost of services (2,711) (2,667)
Sales and marketing costs (1,514) (1,723)
Other operating expenses 0 0
Stock compensation expense [1] 0 0
Segment profit (loss) (2,562) (2,126)
Translational Oncology Solutions [Member]    
Net revenue 7,200 9,286
Direct cost of services (4,877) (3,496)
Sales and marketing costs (2,208) (1,080)
Other operating expenses (4,493) (2,209)
Stock compensation expense [1] 0 0
Segment profit (loss) (4,378) 2,501
Unallocated Corporate Overhead [Member]    
Net revenue 0 0
Direct cost of services 0 0
Sales and marketing costs 0 0
Other operating expenses (3,136) (3,828)
Stock compensation expense [1] (3,162) (2,807)
Segment profit (loss) (6,298) (6,635)
Consolidated [Member]    
Net revenue 8,863 11,550
Direct cost of services (7,588) (6,163)
Sales and marketing costs (3,722) (2,803)
Other operating expenses (7,729) (6,037)
Stock compensation expense [1] (3,162) (2,807)
Segment profit (loss) $ (13,238) $ (6,260)
[1] Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.